DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Bibliographic Details
Main Authors:	Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, Brandon Han Siang Wong, Xinpeng Loh, Aik Seng Ng, Zun Siong Low, Praseetha Prasannan, Chun Gong, Michelle Guet Khim Tan, Chandramouli Nagarajan, Dachuan Huang, Pang Wan Lu, Jing Quan Lim, Sharon Barrans, Choon Kiat Ong, Soon Thye Lim, Wee Joo Chng, George Follows, Daniel J. Hodson, Ming Qing Du, Yeow Tee Goh, Suat Hoon Tan, Nicholas Francis Grigoropoulos, Navin Kumar Verma
Format:	Article
Language:	English
Published:	BMC 2021-10-01
Series:	Molecular Cancer
Subjects:	DDX3X mutation Hematolymphoid malignancy Prognosis Tumour metastasis Drug resistance
Online Access:	https://doi.org/10.1186/s12943-021-01437-0

Internet